Sign in to continue:

Saturday, August 1st, 2026

Tianci International, Inc. Files Form 8-K With Nasdaq: Company Details, Address, and Stock Information for July 2026




Tianci International, Inc. Grants Equity Under 2024 Equity Incentive Plan

Tianci International, Inc. Announces Equity Grants to Senior Executives and Key Personnel

Tianci International, Inc. (Nasdaq: CIIT) has announced the grant of equity awards under its 2024 Equity Incentive Plan, a move that could have significant implications for current and potential investors.

Key Highlights from the Report

  • Date of Report: July 29, 2026
  • Form Type: 8-K (Current Report)
  • Equity Grants: 100,000 shares of the Company’s common stock were granted under the 2024 Equity Incentive Plan.
  • Recipients:
    • 85,000 shares were allocated to three key officers:
      • Shufang Gao, Chief Executive Officer: 45,000 shares
      • Wei Fang, Chief Financial Officer: 20,000 shares
      • Ying Deng, Vice President: 20,000 shares
    • The remaining 15,000 shares were granted to an employee and a consultant of the Company.
  • Plan Approval: The grants were made in accordance with the Company’s 2024 Equity Incentive Plan, as approved by the Compensation Committee of the Board of Directors.

Implications for Shareholders

  • Potential Price Sensitivity: The equity grants to senior management and key personnel represent a significant allocation of new shares, which could have a dilutive effect on existing shareholders. Investors should consider the dilution impact when assessing the Company’s valuation.
  • Alignment of Interests: The issuance of equity incentives is designed to align the interests of management and key employees with those of shareholders, potentially incentivizing performance and long-term value creation.
  • Confidence in Leadership: The substantial allocation of equity to the CEO and other executives may signal the Board’s confidence in its leadership team and their importance to the Company’s strategic direction.
  • Nasdaq Listing: Tianci International, Inc.’s common stock continues to be listed on the Nasdaq Capital Market under the symbol CIIT, providing liquidity and visibility for shareholders.
  • Emerging Growth Company Status: The Company does not qualify as an emerging growth company, potentially subjecting it to more rigorous reporting and compliance requirements.

Additional Background and Company Information

  • Company Address: Unit 1109, Lippo Sun Plaza, 28 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong
  • Contact Phone: +852 2662-1800
  • SEC File Number: 001-42591
  • Tax Identification Number: 45-5540446
  • Former Names: Previously known as Steampunk Wizards, Inc. and Freedom Petroleum Inc., with name changes in 2015 and 2012 respectively.

What Investors Should Watch

  • Share Dilution: Investors should monitor the impact of the 100,000 new shares on the Company’s total outstanding share count and potential EPS dilution.
  • Executive Retention and Performance: Tracking how these equity grants affect executive retention, motivation, and performance metrics will be important for understanding future Company performance.
  • Future Announcements: Additional equity grants or changes to the equity incentive plan could further impact share value or Company strategy.

Conclusion

The equity grants to Tianci International’s top executives and key personnel represent a major development for the Company. While such grants can drive alignment and performance, they also introduce dilution risks that shareholders should consider closely. This action by the Compensation Committee underscores a focus on leadership stability and incentivization as the Company moves forward.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own due diligence before making any investment decisions. The author and publisher are not responsible for any actions taken based on the information contained herein.




View Tianci International, Inc. Historical chart here



NRC Health 2025 Executive Compensation and Corporate Governance Overview

NRC Health 2025 10-K/A: Key Highlights for Investors NRC...